AU2003286499A1 - Interference with c-maf function in multiple myeloma - Google Patents

Interference with c-maf function in multiple myeloma

Info

Publication number
AU2003286499A1
AU2003286499A1 AU2003286499A AU2003286499A AU2003286499A1 AU 2003286499 A1 AU2003286499 A1 AU 2003286499A1 AU 2003286499 A AU2003286499 A AU 2003286499A AU 2003286499 A AU2003286499 A AU 2003286499A AU 2003286499 A1 AU2003286499 A1 AU 2003286499A1
Authority
AU
Australia
Prior art keywords
interference
multiple myeloma
maf
function
maf function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003286499A
Other versions
AU2003286499A8 (en
Inventor
Elaine Hurt
Michael Kuehl
Louis M. Staudt M.D. Ph.D.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2003286499A1 publication Critical patent/AU2003286499A1/en
Publication of AU2003286499A8 publication Critical patent/AU2003286499A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003286499A 2003-10-17 2003-10-17 Interference with c-maf function in multiple myeloma Abandoned AU2003286499A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/033162 WO2005046731A1 (en) 2003-10-17 2003-10-17 Interference with c-maf function in multiple myeloma

Publications (2)

Publication Number Publication Date
AU2003286499A1 true AU2003286499A1 (en) 2004-06-06
AU2003286499A8 AU2003286499A8 (en) 2005-06-06

Family

ID=34589281

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003286499A Abandoned AU2003286499A1 (en) 2003-10-17 2003-10-17 Interference with c-maf function in multiple myeloma

Country Status (2)

Country Link
AU (1) AU2003286499A1 (en)
WO (1) WO2005046731A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008045955A2 (en) 2006-10-10 2008-04-17 Mayo Foundation For Medical Education And Research Inhibiting cyclin d polypeptides
KR101944555B1 (en) 2010-10-06 2019-02-01 펀다시오 인스티튜트 드 르세르카 바이오메디카(아이알비 바르셀로나) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
BR112014030750A2 (en) 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats METHOD FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF LUNG CANCER METASTASIS
EP2703005A1 (en) * 2012-09-04 2014-03-05 Università Degli Studi Di Torino Inhibitors of alpha6 Integrin/E-Cadherin Complex
US20150218213A1 (en) * 2012-09-04 2015-08-06 Università Degli Studi Di Torino Inhibitors of alpha6 integrin/e-cadherin complex
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
EP2906718B1 (en) 2012-10-12 2019-05-15 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
KR20150122731A (en) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) Method for the prognosis and treatment of cancer metastasis
KR20150122786A (en) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) Method for the diagnosis, prognosis and treatment of cancer metastasis
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
WO2015052583A2 (en) 2013-10-09 2015-04-16 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
EP3229909B1 (en) 2014-12-11 2020-10-14 Inbiomotion S.L. Binding members for human c-maf
EP3090751A1 (en) 2015-05-06 2016-11-09 Université de Lausanne Molecular profiling of cd8 t-cells in autochthonous melanoma identifies maf as driver of exhaustion
MX2018014279A (en) 2016-05-25 2019-07-08 Inbiomotion Sl Therapeutic treatment of breast cancer based on c-maf status.
CA3082728A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status

Also Published As

Publication number Publication date
WO2005046731A1 (en) 2005-05-26
AU2003286499A8 (en) 2005-06-06

Similar Documents

Publication Publication Date Title
AU2003272930A1 (en) Footwere
AU2003902455A0 (en) Cadmas
AU2003286499A1 (en) Interference with c-maf function in multiple myeloma
AU2003274573A1 (en) Deburrer
AU2003241210A1 (en) Videocomputer
AU2003232657A1 (en) Clothing with particular function
AU2003100006A4 (en) Adcaster
AU2003100198A4 (en) Colourband Browbands
AU2003100325A4 (en) Freez-A-Cube
AU2003100378A4 (en) Scootermansydney
AU2003100942A4 (en) Energenz
AU2003900402A0 (en) Stillage
AU2003900486A0 (en) Waterguard house drencher
AU2003904561A0 (en) Not Given
AU2003904245A0 (en) Not given
AU2003904212A0 (en) Not given
AU2003903955A0 (en) Not given
AU2003903592A0 (en) Not given
AU2003904076A0 (en) Find me
AU2003905171A0 (en) Multigame Selection
AU2003902029A0 (en) Ecourinal
AU2003900000A0 (en) Sunergy
AU2003902574A0 (en) La-bp cecurit
AU2003903022A0 (en) Visible-love management-system
AU2003900904A0 (en) Soupermatic

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 19, NO 28, PAGE(S) 1859 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, APPLICATION NO. 2003286499, UNDER INID (43) CORRECT THE DATE TO READ 06.06.2005

MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase